High-dose-rate surface brachytherapy as a treatment option for renal cell carcinoma cutaneous metastases

Łukasz Raszewski, MD¹, Artur J. Chyrek, MD², Magdalena Marciniak, MD³, Wojciech M. Burchardt, MD, PhD², Grzegorz M. Bieleń, MSc⁴, Adam Chicheł, MD, PhD²

¹Radiotherapy Department III, Greater Poland Cancer Centre, Poznań, Poland, ²Brachytherapy Department, Greater Poland Cancer Centre, Poznań, Poland, ³Radiotherapy Department II, Greater Poland Cancer Centre, Poznań, Poland, ⁴Electroradiology Department, Poznan University of Medical Sciences, Poznań, Poland, ⁵Medical Physics Department, Greater Poland Cancer Centre, Poznań, Poland

The research was conducted at the Brachytherapy Department, Greater Poland Cancer Centre, Poznań, Poland.

Abstract

Purpose: The aim of this study was to present a case of complete clinical response of renal clear cell carcinoma cutaneous metastases after high-dose-rate surface brachytherapy (HDR sBT).

Material and methods: An 81-year-old female diagnosed with stage IV clear cell renal carcinoma reported to our center with painful relapse of two cutaneous metastases after a previous metastasectomy. The patient was disqualified from systemic therapy due to comorbidities, and qualified to attempt a treatment using HDR sBT. The unit equipped with an iridium-192 source was used to deliver 36 Gy/6 Gy in 6 fractions twice weekly. Overall treatment time was 18 days.

Results: Two weeks after HDR sBT, complete response was observed in one irradiated location, while the partial response was observed in the latter. EORTC grade 1 skin toxicity was reported in both irradiated fields. Three and five months after the treatment, the patient presented complete response and pain relief in both locations with no signs of relapse. The patient remained in palliative care and died seven months after the treatment due to sudden cardiac death.

Conclusions: HDR sBT can be a valuable treatment option for cutaneous metastatic renal cell carcinoma, especially for patients with significant comorbidities. The treatment provided was associated with low toxicity and excellent clinical outcome.

Keywords: renal cell carcinoma, skin metastases, palliative therapy, HDR brachytherapy.

Purpose

Renal cell carcinoma (RCC) accounts for 3% of all cancer diagnoses and cancer-related deaths worldwide, and its incidence is growing [1]. The most common histologic sub-type is clear cell renal cell carcinoma, representing 70% of all RCCs [2]. Up to 20% of patients with newly diagnosed RCC present synchronous distant metastases, and 20% of patients with initially locoregional disease are expected to develop metastatic renal cell carcinoma (mRCC) during surveillance [3, 4]. The most common mRCC locations are lungs, bones, liver, and an opposite kidney [5]. Cutaneous metastases are occasional manifestations of mRCC, with the incidence varying from 2.8% to 3.8% [6, 7]. The development of molecular biology and genomics of RCC resulted in first- and second-line treatments of mRCC based on immunotherapy, including tyrosine kinase inhibitors (TKIs), targeted therapy against vascular growth factor (VEGF), inhibitors of mammalian kinase target of rapamycin (mTOR), and immune checkpoint inhibitors (ICI) of anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) [8-10]. Median overall survival (OS) of patients with stage IV mRCC treated with a combination of ICI and TKIs or other targeted therapies varied from 26.0 to 35.7 months [11, 12]. According to the European Society for Medical Oncology (ESMO) guidelines, therapeutic options for patients who are not eligible for systemic therapy include observation, metastasectomy alone and external beam irradiation, with conventional radiotherapy (CRT), stereotactic radiosurgery (SRS), and stereotactic body radiation therapy (SBRT) [13, 14]. The present case report shows the potential benefits of high-dose-rate surface...
brachytherapy (HDR sBT) for cutaneous metastatic renal cell carcinoma (cmRCC).

Material and methods

Patient status

An 81-year-old female was admitted to our center with metastatic clear cell RCC. In 2004, the patient was diagnosed with a tumor located in the right kidney and underwent right nephrectomy. Histopathology report presented pT1a grade 1 (G1) adenocarcinoma clarocellular tumor, with expression of CK AE1/AE3 (+), RCC (+), Pax8 (+), CD10 (+), VIM (+), and Ki67 50%. According to the ESMO guidelines for stage I RCC, no adjuvant treatment was administered, and the patient remained in surveillance [10]. In 2015, the patient was diagnosed with a 47 × 58 × 78 mm tumor mass located in the left kidney, and underwent intra-arterial transcatheter renal artery embolization. No material for histopathology was obtained, and the patient continued surveillance. In 2018, the patient manifested two painful on palpation abscesses in the left parietal and occipital region, which were initially treated by a dermatologist with topical steroids and fusidic acid. Following the lack of response to dermatological treatment, surgical excision was performed. Histopathology report confirmed metastatic spread of the clear cell RCC with positive surgical margins, and the patient was referred to medical oncology department. Due to an advanced age, WHO-III performance score, and multiple comorbidities, such as chronic heart failure NYHA III with pectoral angina CCS II controlled with implantable cardioverter-defibrillator (ICD), stage IV chronic kidney disease, insulin-dependent type 2 diabetes, and hypertension with three cerebrovascular accidents in the past, the patient was disqualified by a medical oncologist from palliative treatment, with TKIs or immunotherapy, and no further diagnostic imaging was performed. The patient was referred to brachytherapy department to consider local palliative treatment of painful lesions.

One month after the excision, on admission to our Center, the patient presented a scar with visible skin tumor relapse (1 cm in diameter) surrounded by extensive palpable subcutaneous infiltration in left parietal region and a 2 cm long scar after the excision located in occipital region, with not visible but palpable subcutaneous residual mass. Both locations were painful to touch as well as at supine position, despite the use of oral tramadol 75 mg thrice daily. Additional two palpable but painless subcutaneous metastases located in right subscapular and left gluteal region were identified. A radiation oncologist qualified the patient for an attempt of HDR sBT for painful and function-compromising lesions, and further best supportive care (BSC).

Brachytherapy treatment

The patient was qualified for palliative HDR sBT of lesions located in the left parietal and left occipital regions. The tumors’ borders were set with on-skin markers (Figures 1 and 2), and two sets of individual flap applicators (Freiburg Flap, Elekta Brachytherapy) combined with five single-leader catheters for parietal and 2 for occipital tumor (Figure 3) were prepared and adjusted to the patient’s skin. Afterwards, the applicators’ positions were

Fig. 1. Tumor relapse after metastasectomy surrounded by extensive palpable subcutaneous infiltration in left parietal region. A set of on-skin markers were used to enable visualizing borders of target volumes on CT scan

Fig. 2. Scar after metastasectomy located in left occipital region, with palpable residual mass. A set of on-skin markers were used to enable visualizing borders of target volumes on CT scan

Fig. 3. Two sets of individual flap applicators (Freiburg Flap, Elekta Brachytherapy) combined with 5 single-leader catheters for parietal and 2 single-leader catheters for occipital tumor
marked with a waterproof pen, and computed tomography (CT) scan of the head and neck region was performed with a 1 mm slice thickness. 3D treatment planning was completed with the OncentraBrachy system (Nucletron, an ELEKTA company, ELEKTA AB, Stockholm, Sweden) by delineating two clinical targets volumes (CTVs). CTV1 covered tumor in the left parietal region, with maximum depth of CTV = 4.5 mm and volume = 1.91 cc, while CTV2 included lesion in the left occipital region, with maximum depth of CTV = 3.5 mm and volume = 1.39 cc (Figures 4 and 5). There were no margins added to CTVs. Target volumes were specified basing on clinical examination, pathology report, and the lesion seen on CT scans. Organs at risk (OARs) were delineated, including adjacent bones and eye lenses. Subsequently, a medical physicist reconstructed the applicators digitally. The source positions above the CTVs were activated to plan an optimal dose distribution. The axis dose points were added and adapted to the thickness of the lesion, or the applicator points were added manually and adapted to the deeper surface of the lesion. Dose distribution was normalized to the defined points and then optimized using dose-point...
Results

The patient completed the scheduled treatment presenting grade 1 acute skin erythema, according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) Radiation Toxicity scoring. Two weeks after HDR sbT, the tumor in the parietal region (Figure 6) presented partial clinical response and complete clinical response, with no palpable tumor observed in the occipital region (Figure 7). Adjacent skin demonstrated local healing process, with RTOG/EORTC grade 1 erythema with dry desquamation, alopecia, and pruritus. Similar clinical status with proper healing process was observed 6 weeks after the treatment, with a significant additional reduction of oral analgesics (reduction of morphine equivalent from 25 to 15 mg). Three and five months after the procedure, the patient presented complete clinical response in the parietal region (Figure 8) and no clinical signs of relapse in the occipital region (Figure 9), with a further reduction of opioid drugs usage. Both irradiated regions presented RTOG/EORTC grade 1 skin depigmentation and grade 2 hair loss. However, clinical progression of non-irradiated cutaneous metastases was noted, with one additional subcutaneous tumor in the right forearm. The patient died 7 months after the completion of HDR sbT due to sudden cardiac death, with no clinical signs of progression in the irradiated fields.

Discussion

Cutaneous metastases of RCC are rare manifestations of mRCC, and represent 6% of all cutaneous metastases [15]. Median OS of patients with cmRCC varies from 6 to 12 months, and is worse compared to 26-36 months in patients with non-cutaneous metastases [16, 17]. Treatment modalities, which can improve OS for patients with mRCC, include systemic therapy alone or combined with cytoreductive nephrectomy, stereotactic ablative radiation therapy (SABR), and metastasectomy. However, considering the potential drug resistance and significant toxicity associated with these modalities, an alternative

| Parameter | CTV1 | CTV2 |
|-----------|------|------|
| Volume    | 1.91 cc | 1.39 cc |
| Max depth | 4.5 mm  | 3.5 mm  |
| D90       | 101.94% | 110.14% |
| D100      | 86.86%  | 94.36%  |
| V100      | 94.17%  | 99.38%  |
| V150      | 1.12%   | 18.16%  |
| Bones D0.1 | 91.53% |
| Bones Dmax | 93.3%   |

CTV – clinical target volume

optimization with a distance option (Table 1). For CTV1, the physician and physicist decided to irradiate the target in the parietal region, using 4 out of 5 single-leader catheters due to sufficient CTV coverage and favorable dose distribution with 4 catheters. The total dose of 36 Gy (reference dose) in 6 fractions was planned, and two fractions per week were scheduled for both CTVs, closing the overall treatment time in 18 days. Outpatient treatment was performed simultaneously for both CTVs using a MicroSelectron HDR-BT unit (Nucletron, an Elekta Company, Stockholm, Sweden) equipped with an iridium-192 (192Ir) radioactive source, characterized by average radiation energy of 0.38 MeV and nominal activity around of 370 GBq (reference air-kerma rate, 41 mGy/h). Lead apron covering ICD location was applied at each fraction to ensure cardiac safety of the treatment.
approach may be required [13, 14, 18, 19]. The role of radiation therapy in the treatment of mRCC was limited to symptomatic palliative radiation therapy due to the common opinion that RCC is relatively radioresistant comparing to other tumors [20]. The opinion was based on multiple studies on in vitro RCC cell lines. Syljuasen et al. and Ning et al. demonstrated that the surviving fraction of RCC cell lines after irradiating with a single dose of 2 Gy (SF2) ranged from 0.37 to 0.60, presenting the highest rate from all examined cell types [21, 22]. Leung et al. presented that RCC cell lines vary in radiosensitivity depending on glutathione concentration, explaining unexpected variation in SF2 [23].

However, Deschavanne et al. in their meta-analysis indicated that α/β ratio (ratio describing tissue sensitivity to change of fraction dose or dose-rate) used to present biologically effective dose (BED) in linear-quadratic model is relatively low (between 2.6 and 4.2), highlighting that potential benefit can be obtained using higher than conventional fractionation dose [24]. The tendency to use hypofractionation in RCC oligometastatic radiotherapy is currently expressed in the number of ongoing clinical trials investigating the use of SABR with encouraging LC and OS results, but these reports relate to visceral metastatic disease only [18, 25-27]. Gay et al. presented the only accessible in the literature case report on the treatment for cutaneous mRCC with hypofractionated EBRT [28]. The five-week-long treatment using electron beam radiotherapy and a custom on-skin bolus, included 13 fractions of 3.75 Gy to a total dose of 48.75 Gy for a 2 cm tumor located in a preauricular region. It resulted in complete clinical response with a good normal tissue tolerance and significant pain reduction, until unrelated to irradiated field death of patient 10 months after the treatment. To describe this regimen’s radiobiological features, the authors used α/β ratio equal to 10 for tumor response, which seems to be overstated regarding the above-mentioned scientific reports. A different radiobiological foundation is shown in the present case study by using a three-week-long regimen with 6 Gy per fraction, twice weekly to a total dose of 36 Gy, using HDR sBT for definite treatment. The total delivered dose and fractionation schedules aimed at pain alleviation, function restoration, complete local eradication of cancer cells, and shortening of overall treatment time (OTT). This regimen’s rationale was based on the assumption that tumors with low α/β ratio, such as cm-RCC, are more prone to fractionation dose variability than skin tumors with high α/β ratio, i.e., squamous cell skin carcinomas [29]. Therefore, the total physical dose de-escalation, reduction of the normal tissues irradiated volume, and shortening of OTT were allowed. The efficiency of both regimens were evaluated using BED and equivalent doses in 2 Gy fraction (EQD2). For the purpose of this comparison, α/β ratio = 2.6 was adapted, and BED was calculated using equation BED = n × d × (1 + d/α/β), where n is the number of treatment fractions, d - dose per fraction in Gray (Gy), and α/β = α/β ratio [30]. BED2.6 for sBT regimen was 119.1 Gy and for hypofractionated EBRT, BED2.6 was also 119.1 Gy. EQD2 were also counted for both scenarios using equation formula EQD2 = D × ([d + (α/β)]/[2 + (α/β)]), where D is total dose given in Gy, d is dose per fraction in Gy, and α/β is α/β ratio, resulting in EQD2 = 67.3 Gy for sBT and hypofractionated EBRT regimens. Both schedules provided the same treatment results and normal tissue toxicity, while the sBT regimen allowed the delivery of total prescribed doses in a more convenient pattern, with fewer fraction-related hospital visits and shorter OTT than the EBRT regimen. Furthermore, sBT allowed to omit dose build-up at the skin surface; thus, it did not require on-skin bolus, enabling more heterogenic dose distribution in more challenging locations, as compared to EBRT [31]. Late normal tissue tolerance and cosmesis assessment require longer observation period, which may be difficult considering poor OS in this group of patients; nonetheless, the post-treatment cosmesis after sBT is expected to improve, as compared to EBRT [32]. Zaorsky et al. in SCRiBE meta-analysis evaluated data of 24 studies fo-
focussing on clinician-reported post-treatment cosmesis of 3,399 patients with basal cell carcinoma or squamous cell carcinoma, treated with either EBRT or sBT. To compare BEDs of applied fractionation regimens, α/β ratio of 3.0 was adapted, and BED3Gy were calculated. For regimens with BED3Gy > 100 Gy (which included both EBRT regimen used by Gay et al. [28] and sBT regimen presented in our case study), post-treatment cosmesis was favorable for sBT procedures when compared to EBRT regimens: 95% of sBT treated cases were classified as “good” cosmesis, while 79% of EBRT treated cases were classified as “good” with an increasing amount of “fair” cosmesis. Further investigation with a larger group of patients is needed to assess long-term local control, feasibility in both palliative and oligometastatic scenarios, and possible profits arising from sequential use of immunotherapy with sBT, including abscopal effect remaining metastatic lesions [33].

Conclusions

High-dose-rate sBT can be a useful definite treatment option for focal renal cancer skin metastases, especially for patients who are not eligible for other treatment modalities or lesion causing organ dysfunction and/or pain. The flap applicators and 3D treatment planning system allowed to optimize the dose inside CTVs while sparing normal tissues. The provided treatment resulted in excellent local control and reduced pain level. To the best of our knowledge, the presented case study is the first to report the feasibility and efficiency of sBT in management of cmRCC.

Disclosure

The authors report no conflict of interest.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30.
2. Moch H, Cubilla AL, Humphrey PA et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 2016; 70: 93-105.
3. Dabestani S, Thorstenson A, Lindblad P et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 2016; 34: 1081-1086.
4. Capitanio U, Bensalah K, Bev A et al. Epidemiology of renal cell carcinoma. Eur Urol 2019; 75: 74-84.
5. Bianchi M, Sun M, Jeldres C et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012; 23: 973-980.
6. Ohlsson R, Geertsen L, Stuveseth SB et al. Cutaneous metastases in renal cell carcinoma: a systematic review and a case report. Scand Urol Nephrol 2019; 53: 9-13.
7. Lockingill DP, Spangler N, Helm KE. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 1993; 29 (2 Pt 1): 228-236.
8. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017; 376: 354-366.
9. Lalani AKA, McGregor BA, Albigez L et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions. Eur Urol 2019; 75: 100-110.
10. Rassy E, Filippot R, Albigez L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol 2020; 12: 175883952097504.
11. Motzer RJ, Tanmir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378: 1277-1290.
12. Powles T, Plimack ER, Souiléres D et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020; 21: 1563-1573.
13. Escudier B, Porta C, Schmidinger M et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 706-720.
14. Dabestani S, Marconi L, Hofmann F et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 2014; 15: e549-e561.
15. Williams JC, Heaney JA. Metastatic renal cell carcinoma presenting as a skin nodule: case report and review of the literature. J Urol 1994; 152: 2094-2095.
16. Onak Kandemir N, Barut F, Kivanc Y et al. Renal cell carcinoma presenting with cutaneous metastasis: a case report. Case Rep Med 2010; 2010: 913734.
17. Urakci Z, Kaplan MA, Küçüktüner M. Renal cell carcinoma presenting with cutaneous metastasis: case report. Turk J Oncol 2013; 28: 163-166.
18. Zaorsky NG, Lehrer EJ, Kothari G et al. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol 2019; 2: 515-523.
19. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
20. DiBiase SJ, Valcnti RK, Schultz D et al. Palliative irradiation for focally symptomatic metastatic renal cell adenocarcinoma: support for dose escalation based on a biological model. J Urol 1997; 158: 746-749.
21. Syljuasen RG, Beldegrun A, Tso CL et al. Sensitization of renal carcinoma to radiation using alpha interferon gene transfection. Radiat Res 1997; 148: 443-448.
22. Ning S, Trisler K, Wessels BW et al. Radiobiological studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 1997; 80: 2519-2528.
23. Leung SW, Mitchell JB, al-Nabulsi I et al. Effect of L-buthathione sulfoximine on the radiation response of human renal cell carcinoma cell lines. Cancer 1993; 71: 2276-2285.
24. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol 1996; 34: 251-266.
25. Altoos BM, Amini A, Bourlon MT et al. Is RCC truly radioresistant? Local control rates of metastatic renal cell carcinoma (RCC) to the lung using stereotactic radiotherapy (SBRT). J Clin Oncol 2015; 33: 445.
26. Siva S, Kothari G, Muavecovic A et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol 2017; 14: 549-563.
27. Palma DA, Olson R, Harrow S et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; 393: 2051-2058.
28. Gay HA, Cavaliere R, Allison RR et al. Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. Dermatol Online J 2007; 13: 6.
model, derived from clinical radiotherapy studies. Radiat Oncol 2018; 13: 96.
30. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62: 679-694.
31. Likhacheva AO, Devlin PM, Shirvani SM et al. Skin surface brachytherapy: A survey of contemporary practice patterns. Brachytherapy 2017; 16: 223-229.
32. Zaorsky NG, Lee CT, Zhang E et al. Skin Cancer Brachytherapy vs External beam radiation therapy (SCRIBE) meta-analysis. Radiother Oncol 2018; 126: 386-395.
33. Suzuki G, Masui K, Yamazaki H et al. Abscopal effect of high-dose-rate brachytherapy on pelvic bone metastases from renal cell carcinoma: a case report. J Contemp Brachytherapy 2019; 11: 458-461.